ALNY•benzinga•
Alnylam Pharmaceuticals shares are trading higher after the company announced results from the APOLLO-B Phase 3 study of patisiran for transthyretin-mediated amyloidosis with cardiomyopathy.
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 8, 2022 by benzinga